SCHEMBL18374697

SCHEMBL18374697

CC(=O)SCCCCCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 3/20 0.55
HDAC3 O15379 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
HDAC9 Q9UKV0 2/20 0.55
HDAC5 Q9UQL6 2/20 0.55
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP2D6 P10635 1/20 0.51
MEN1 O00255 1/20 0.51
CHRM2 P08172 1/20 0.51
MAOB P27338 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29386458 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL29990582 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL29991896 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL25123876 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL900820 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL25123844 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL30601912 1.00 HDAC8 (0.55) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL29387341 0.98 CYP1A2 (0.53) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL18374069 0.98 CYP1A2 (0.53) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL9970727 0.94 CYP1A2 (0.58) KMT2ACYP1A2CYP2C19CYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117715904-A CDK2 degrading agents and uses thereof 凯麦拉医疗公司 2024-03-15 CN disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 EP disclosed
US-20230126280-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-04-27 US disclosed
US-20230126280-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-04-27 US disclosed
US-11584723-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-02-21 US disclosed
US-20220402879-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-12-22 US disclosed
US-11518746-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-12-06 US disclosed
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 US disclosed
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 US disclosed
US-11014924-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-05-25 US disclosed
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20190276410-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-12 US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 US disclosed
WO-2018128720-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 WO disclosed
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 US disclosed
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 US disclosed
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-05 US disclosed
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-05 US disclosed
WO-2018098204-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed
WO-2017006282-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2017-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885
US-11584723-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD HDAC8 2190/4885HDAC3 2085/4885HDAC4 2580/4885
US-20220402879-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885
US-11014924-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885
US-11518746-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors DUT, DPYD, TYMP HDAC8 1546/4885HDAC3 2006/4885HDAC4 2427/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT HDAC8 1609/4885HDAC3 2221/4885HDAC4 2457/4885
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885
US-20190276410-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, DPYD, TYMP HDAC8 1546/4885HDAC3 2006/4885HDAC4 2427/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD HDAC8 2190/4885HDAC3 2085/4885HDAC4 2580/4885
US-20230126280-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.